Ru Han

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 15

Top Topics

Systematic Review

Men Who Have Sex With Men

Hepatitis C Virus Infection

Top Venues

Human vaccines & immunotherapeutics

Infectious diseases and therapy

Journal of market access & health policy

Applied health economics and health policy

This page only lists publications with an associated author ORCID identifier.

Publications

Ru Han, Peter Franz M San Martin, Nurilign Ahmed, Adriana Guzmán-Holst, Ahmed Mohy, Thatiana de Jesus Pereira Pinto, Bruna M G de Veras, Jorge A Gomez, Gyneth Lourdes Bibera, Désirée A M van Oorschot
Modelling the Public Health Burden of Herpes Zoster and the Impact of Adjuvanted Recombinant Zoster Vaccine in Five Selected Countries in Southeast Asia. Infectious diseases and therapy 13 (4) (2024)
Ru Han, Peter Franz M San Martin, Nurilign Ahmed, Adriana Guzmán-Holst, Ahmed Mohy, Thatiana de Jesus Pereira Pinto, Bruna M G de Veras, Jorge A Gomez, Gyneth Lourdes Bibera, Désirée A M van Oorschot
Modelling the Public Health Burden of Herpes Zoster and the Impact of Adjuvanted Recombinant Zoster Vaccine in Five Selected Countries in Southeast Asia. Infectious diseases and therapy 13 (4) (2024)
Ru Han, Peter Franz M San Martin, Nurilign Ahmed, Adriana Guzmán-Holst, Ahmed Mohy, Thatiana de Jesus Pereira Pinto, Bruna M G de Veras, Jorge A Gomez, Gyneth Lourdes Bibera, Désirée A M van Oorschot
Modelling the Public Health Burden of Herpes Zoster and the Impact of Adjuvanted Recombinant Zoster Vaccine in Five Selected Countries in Southeast Asia. Infectious diseases and therapy 13 (4) (2024)
Ru Han, Peter Franz M San Martin, Nurilign Ahmed, Adriana Guzmán-Holst, Ahmed Mohy, Thatiana de Jesus Pereira Pinto, Bruna M G de Veras, Jorge A Gomez, Gyneth Lourdes Bibera, Désirée A M van Oorschot
Modelling the Public Health Burden of Herpes Zoster and the Impact of Adjuvanted Recombinant Zoster Vaccine in Five Selected Countries in Southeast Asia. Infectious diseases and therapy (2024)
Ru Han, Peter Franz M San Martin, Nurilign Ahmed, Adriana Guzmán-Holst, Ahmed Mohy, Thatiana de Jesus Pereira Pinto, Bruna M G de Veras, Jorge A Gomez, Gyneth Lourdes Bibera, Désirée A M van Oorschot
Modelling the Public Health Burden of Herpes Zoster and the Impact of Adjuvanted Recombinant Zoster Vaccine in Five Selected Countries in Southeast Asia. Infectious diseases and therapy 13 (4) (2024)
Ru Han, Peter Franz M San Martin, Nurilign Ahmed, Adriana Guzmán-Holst, Ahmed Mohy, Thatiana de Jesus Pereira Pinto, Bruna M G de Veras, Jorge A Gomez, Gyneth Lourdes Bibera, Désirée A M van Oorschot
Modelling the Public Health Burden of Herpes Zoster and the Impact of Adjuvanted Recombinant Zoster Vaccine in Five Selected Countries in Southeast Asia. Infectious diseases and therapy 13 (4) (2024)
Ru Han, Jorge A Gomez, Bruna M G de Veras, Thatiana de Jesus Pereira Pinto, Adriana Guzmán-Holst, Javier Nieto Guevara, Désirée A M van Oorschot
How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be? Human vaccines & immunotherapeutics 19 (1) (2023)
Ru Han, Jorge A Gomez, Bruna M G de Veras, Thatiana de Jesus Pereira Pinto, Adriana Guzmán-Holst, Javier Nieto Guevara, Désirée A M van Oorschot
How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be? Human vaccines & immunotherapeutics 19 (1) (2023)
Ru Han, Jorge A Gomez, Bruna M G de Veras, Thatiana de Jesus Pereira Pinto, Adriana Guzmán-Holst, Javier Nieto Guevara, Désirée A M van Oorschot
How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be? Human vaccines & immunotherapeutics (2023)
Ru Han, Jorge A Gomez, Bruna M G de Veras, Thatiana de Jesus Pereira Pinto, Adriana Guzmán-Holst, Javier Nieto Guevara, Désirée A M van Oorschot
How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be? Human vaccines & immunotherapeutics 19 (1) (2023)
Ru Han, Jorge A Gomez, Bruna M G de Veras, Thatiana de Jesus Pereira Pinto, Adriana Guzmán-Holst, Javier Nieto Guevara, Désirée A M van Oorschot
How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be? Human vaccines & immunotherapeutics 19 (1) (2023)
Ru Han, Jorge A Gomez, Bruna M G de Veras, Thatiana de Jesus Pereira Pinto, Adriana Guzmán-Holst, Javier Nieto Guevara, Désirée A M van Oorschot
How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be? Human vaccines & immunotherapeutics 19 (1) (2023)
Ru Han, Shuyao Liang, Clément François, Samuel Aballea, Emilie Clay, Mondher Toumi
Allocating treatment resources for hepatitis C in the UK: a constrained optimization modelling approach. Journal of market access & health policy 9 (1) (2021)
Ru Han, Clément François, Mondher Toumi
Systematic Review of Health State Utility Values Used in European Pharmacoeconomic Evaluations for Chronic Hepatitis C: Impact on Cost-Effectiveness Results. Applied health economics and health policy 19 (1) (2021)
Ru Han, Junwen Zhou, Clément François, Mondher Toumi
Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update. BMC infectious diseases 19 (1) (2019)